Health
Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus – News-Medical.Net
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
Noosa News22 hours agoIKEA Has Just Revealed Its Collab with Trendsetting Designer Gustaf Westman, Bringing Sculptural Shapes to the Holiday Season
-
General21 hours agoThree men to be sentenced over Mid North Coast Correctional Centre bashing
-
Noosa News23 hours agoMan injured, cars destroyed at Tyres and More shop
-
General22 hours agoNepal’s PM quits as anti-corruption protests spiral